81 / 1674
OncotypeDX
(Genomic Health, USA)
HR+
/ HER2- , T1-3, N-/N+
FFPE samples
21 GENES
PROLIFERATION, ESTROGEN,
HER2, INVASION (16 GENES) + REFS (5 GENES)
CENTRALIZED
RECURRENCE (10 years)
BENEFIT TO ADJUVANT CT
LOW RISK (RS<18):
+ HT / NO CHEMOTHERAPY
INTERMEDIATE:
DISCUSSION
HIGH RISK (RS≥31):
+HT / + CHEMOTHERAPY